Workflow
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
CRGXCargo Therapeutics(CRGX) GlobeNewswire·2025-01-10 13:00
  • 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel (firi-cel); Interim analysis results expected to be reported in 1H’25 - - IND application for CRG-023, CARGO’s tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 - - CARGO announces novel allogeneic platform based on a universal allogeneic-enabling vector intended to be paired with any new or existing CAR vector to create an allogeneic CAR T-cell therapy while l ...